NFE2L2 and esophageal squamous cell carcinoma: Cui et al. have explored the genomic abnormalities of 508 ESCC patients and proposed a classifying these tumors into three subgroups: NFE2L2-mutated, with poor prognosis; RTK-RAS-MYC-amplified (tumors with receptor tyrosine kinase/RAS amplification, such as EGFR or FGFR1 amplification, comprising about 50% of cases), with intermediate prognosis; and double-negative, with a better prognosis [35].